BTL Unveils EXOMIND: A New Era in Mental Wellness

Contributed by: PR Newswire

Tags

BTL-EXOMIND

More Like This

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)

GlobeNewswire associated0

Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics

FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro

Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression

PR Newswire associated0

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder

INSIGHTEC ANNOUNCES EXABLATE PRIME AVAILABILITY IN EUROPE -THE NEXT GENERATION OF MR-GUIDED FOCUSED ULTRASOUND

Trial of new psychedelic drug seeks patients with Treatment Resistant Depression

MindMed to Be Added to the Nasdaq Biotechnology Index